Search

Your search keyword '"Foster, MC"' showing total 190 results

Search Constraints

Start Over You searched for: Author "Foster, MC" Remove constraint Author: "Foster, MC"
190 results on '"Foster, MC"'

Search Results

1. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis

2. Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk

3. Genome-wide association for abdominal subcutaneous and visceral adipose reveals a novel locus for visceral fat in women

4. New genetic loci link adipose and insulin biology to body fat distribution.

5. New genetic loci link adipose and insulin biology to body fat distribution

6. Genome-Wide Association and Functional Follow-Up Reveals New Loci for Kidney Function

7. Genome-wide association for abdominal subcutaneous and visceral adipose reveals a novel locus for visceral fat in women

8. Genome-Wide Association and Functional Follow-Up Reveals New Loci for Kidney Function

9. Letters to the editor

10. Relations of measures of endothelial function and kidney disease: the Framingham Heart Study.

11. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study.

12. Using self-help support groups: a framework for nursing practice and research.

13. A total synthesis of indospicine, 6-amidino-2-aminohexanoic acid

15. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial.

16. Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function

17. Genetic studies of body mass index yield new insights for obesity biology

18. New genetic loci link adipose and insulin biology to body fat distribution

19. Common Variants in Mendelian Kidney Disease Genes and Their Association with Renal Function

20. Relation between angiographic lesion severity, vulnerable plaque morphology and future adverse cardiac events (from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study)

21. Cancer-related cognitive impairment in older adults with acute myeloid leukemia treated with hypomethylating agents and venetoclax chemotherapy: a longitudinal descriptive study.

23. Comprehensive genomic profiling reveals molecular subsets of ASXL1 -mutated myeloid neoplasms.

24. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.

25. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.

26. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.

28. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.

29. Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens.

30. Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.

31. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.

32. Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.

33. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.

35. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.

36. Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia.

37. Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains.

38. Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort.

39. Motor Responses in Pediatric Pompe Disease in the ADVANCE Participant Cohort.

40. Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations.

41. Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia.

43. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.

44. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.

45. Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

46. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.

47. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.

48. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.

49. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.

50. Evaluation and optimization of a clinical pharmacist driven transitions of care model for malignant hematology.

Catalog

Books, media, physical & digital resources